pyrazines has been researched along with Hepatitis B in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bell, S; Desmond, PV; Goldberg, R; Smith, E; Thompson, A | 1 |
| Chawla, PS; Kochar, MS | 1 |
| Bandi, P; Booth, CJ; Chisari, FV; Garcia, ML; Robek, MD | 1 |
| Beysel, S; Yağci, M; Yeğın, ZA | 1 |
| Cho, SH; Choi, JY; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, YS; Um, SH; Yu, E | 1 |
| Goh, YT; Han, ST; Hwang, WY; Linn, YC; Mya, DH; Tan, DC | 1 |
| Hashimoto, S; Nakaseko, C; Sakai, S; Sakuma, I; Shimura, T; Takagi, T; Takeda, Y; Tanaka, H | 1 |
| Groopman, JD; Kensler, TW | 1 |
| Chen, B; Davidson, NE; Egner, PA; Enger, C; Fang, X; Gordon, GB; Gorman, MB; Groopman, JD; Helzlsouer, KJ; Jacobson, LP; Kensler, TW; Kuang, SY; Li, YF; Muñoz, A; Prochaska, HJ; Qian, GS; Wang, JB; Wu, Y; Yu, LY; Zarba, A; Zhang, BC; Zhang, QN; Zhu, YR | 1 |
| Alaoui-Jamali, MA; Batist, G; Fotouhi-Ardakani, N; Jaitovitch-Groisman, I; Schecter, RL; Woo, A | 1 |
2 review(s) available for pyrazines and Hepatitis B
| Article | Year |
|---|---|
What's new in clinical pharmacology and therapeutics.
Topics: Abatacept; Acetanilides; Amides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiparkinson Agents; Antirheumatic Agents; Antiviral Agents; Apomorphine; Benzazepines; Cardiovascular Agents; Fumarates; Hepatitis B; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Hypoglycemic Agents; Immunoconjugates; Multiple Sclerosis; Natalizumab; Nucleosides; Papillomavirus Vaccines; Pharmacology, Clinical; Piperazines; Pyrazines; Pyrimidinones; Quinoxalines; Ranolazine; Sitagliptin Phosphate; Smoking Cessation; Telbivudine; Thymidine; Triazoles; Varenicline; Viral Vaccines | 2008 |
Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
Topics: Aflatoxin B1; Aflatoxins; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Carcinogens; Clinical Trials as Topic; Cohort Studies; DNA Adducts; Guanine; Hepatitis B; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Proteins; Pyrazines; Risk Factors; Thiones; Thiophenes | 1996 |
2 trial(s) available for pyrazines and Hepatitis B
| Article | Year |
|---|---|
Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial.
Topics: Adult; Anticarcinogenic Agents; Biomarkers; Biopsy; Collagen; Double-Blind Method; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrazines; Thiones; Thiophenes; Transforming Growth Factor beta1 | 2011 |
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.
Topics: Adult; Aflatoxins; Aged; Anticarcinogenic Agents; Carcinoma, Hepatocellular; China; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Pyrazines; Thiones; Thiophenes | 1997 |
6 other study(ies) available for pyrazines and Hepatitis B
| Article | Year |
|---|---|
Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Hepatitis B; Humans; Male; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib inhibits hepatitis B virus replication in transgenic mice.
Topics: Animals; Antiviral Agents; Boronic Acids; Bortezomib; Cytokines; DNA, Viral; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Immunohistochemistry; Liver; Mice; Mice, Transgenic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Virus Replication | 2010 |
Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hepatitis B; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Comorbidity; Endemic Diseases; Female; Hepatitis B; Humans; Immunologic Factors; Incidence; Lamivudine; Male; Middle Aged; Multiple Myeloma; Prevalence; Prospective Studies; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Stem Cell Transplantation; Transplantation, Autologous; Virus Activation | 2012 |
Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation | 2012 |
Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz.
Topics: Antiviral Agents; Gene Expression Regulation, Enzymologic; Glutathione Transferase; Hepatitis B; Hepatitis B virus; Humans; Isoenzymes; Promoter Regions, Genetic; Pyrazines; RNA, Messenger; Sp1 Transcription Factor; Thiones; Thiophenes; Trans-Activators; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Viral Regulatory and Accessory Proteins | 2000 |